Lab Medicine News
In the News
BRCA1 and BRCA2 added to BROCA Cancer Risk Panel
In response to the Supreme Court's decision in the case of Association For Molecular Pathology et al. v. Myriad Genetics, Inc., et al., the Department of Laboratory Medicine at the University of Washington Medical Center will provide clinical testing for mutations in the BRCA1 and BRCA2 genes as part of the BROCA Cancer Risk Panel effective June 14, 2013.
Testing is performed with next-generation sequencing technology, which detects all classes of disease-causing mutations. The Department's clinical test is based on the research of Drs. Tom Walsh and Mary-Claire King, who first developed this technology to study hereditary risk of breast and ovarian cancer and reported it in 2010.
For more information on testing»
Coming soon: new newsletter content.
Last updated: 05/21/2018